← IndicationsOpen filtered programs
Landscape
OTOF-Related Hearing Loss
OTOF-Related Hearing Loss has 5 tracked records across 5 named organizations, including 3 strong-evidence records and 4 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
5
Pipeline Records
strong evidence + caveats + candidates
3
Strong Evidence
2 checked records with caveats
4
Active Programs
currently active
1
Marketed / Approved
commercial or approved
5
Organizations
companies, sponsors, and institutions
Competitive Density
14/100
organization breadth + program volume
Pipeline Velocity
62/100
active and late-stage share
Evidence Coverage
60/100
share strong evidence
Completion Signal
40/100
late-stage, approved, or marketed
Attrition Rate
0/100
share discontinued
Concentration
20/100
top-organization share
Programs by Stage
Phase 1/22 · 40%
Phase 21 · 20%
Interventional/NA1 · 20%
Approved1 · 20%
Trial / Program Status
Active4 · 80%
Approved1 · 20%
Modality Breakdown
Gene Therapy5 · 100%
Program Types
Therapeutic5 · 100%
Top Organizations
Eli Lilly and Company1 · 20%
Institution-led study1 · 20%
Regeneron Pharmaceuticals1 · 20%
Sensorion1 · 20%
Shanghai EuHearing Therapeutics Co., Ltd1 · 20%
Population Tags
congenital5 · 100%
genetic5 · 100%
pediatric5 · 100%
bilateral4 · 80%
otof-dfnb94 · 80%
pre-lingual4 · 80%
profound4 · 80%
adult2 · 40%
sensorineural1 · 20%
Strong-Evidence Programs
3 recordsOtarmeni by RegeneronStrong evidence
Company: Regeneron Pharmaceuticals · Approved · Approved
Gene TherapyApprovedApproved99% confidence
AK-OTOF by Eli Lilly and AkouosStrong evidence
Company: Eli Lilly and Company · Phase 2 · Active
Gene TherapyPhase 2Active95% confidence
SENS-501 by SensorionStrong evidence
Company: Sensorion · Phase 1/2 · Active
Gene TherapyPhase 1/2Active94% confidence
Checked Records With Caveats
2 recordsEHT102 by EuHearingStatus caveat
Company: Shanghai EuHearing Therapeutics Co., Ltd · Phase 1/2 · Active
Gene TherapyPhase 1/2Active90% confidence
Fudan EH002 OTOF gene therapy studyStatus caveat
Sponsor / Institution: Institution-led study · Interventional/NA · Active
Gene TherapyInterventional/NAActive84% confidence